University of Connecticut

OpenCommons@UConn
University Scholar Projects

University Scholar Program

Spring 5-1-2022

When Problems Become Solutions: Harnessing the Osteogenic
Capacity of Disease-Causing Stem Cells to Repair Bone Fractures
Mehreen Pasha
mehreenpasha19@gmail.com

Follow this and additional works at: https://opencommons.uconn.edu/usp_projects
Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons,
Developmental Biology Commons, Disease Modeling Commons, Genetics Commons, Musculoskeletal
Diseases Commons, Orthopedics Commons, and the Therapeutics Commons

Recommended Citation
Pasha, Mehreen, "When Problems Become Solutions: Harnessing the Osteogenic Capacity of DiseaseCausing Stem Cells to Repair Bone Fractures" (2022). University Scholar Projects. 78.
https://opencommons.uconn.edu/usp_projects/78

Pasha 1

When Problems Become Solutions:
Harnessing the Osteogenic Capacity of
Disease-Causing Stem Cells to Repair Bone
Fractures
Mehreen Pasha
B.S. in Molecular and Cell Biology, Minor in Spanish
University Scholar Committee: Dr. David Goldhamer (Head), Dr. Geoffrey Tanner,
Dr. Adam Zweifach
May 2022

Pasha 2

Table of Contents
Abstract............................................................................................................................................................... 3
Acknowledgments ............................................................................................................................................... 4
Introduction ........................................................................................................................................................ 5
The role of Acvr1 mutant fibro/adipogenic progenitors (FAPs) in fibrodysplasia ossificans progressiva (FOP) ....... 5
Fibro/adipogenic progenitor biology and their role in FOP pathogenesis ................................................................ 7
Cre-dependent knockin mouse model of FOP ........................................................................................................... 8
Bone fractures: preexisting treatments and prevalence ........................................................................................ 10
Hypotheses and experimental aims........................................................................................................................ 11
Materials and Methods ......................................................................................................................................12
Animals ................................................................................................................................................................... 12
Fluorescence-activated cell sorting (FACS) and cell injection ................................................................................. 13
Bone fragment transplantation .............................................................................................................................. 14
Cardiotoxin-mediated injury to trigger HO in Acvr1tnR206H/+;R26NG/+;Tie2-Cre mouse model .................................. 14
Micro-CT ................................................................................................................................................................. 15
Results ...............................................................................................................................................................16
Bone fragment transplantation and Acvr1 mutant FAP injection into SHO-PrkdcscidHrhr hosts form HO that is not
highly localized to bone fragments ........................................................................................................................ 16
Bone fragment transplantation into Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts forms HO that is not highly localized to
bone fragments ...................................................................................................................................................... 19
Discussion and Future Directions ........................................................................................................................23
References .........................................................................................................................................................29

Pasha 3

Abstract
While we often perceive disease as negative, there is potential to engineer seemingly
negative biological phenomena into therapeutics to treat a variety of human illnesses.
Fibrodysplasia ossificans progressiva (FOP) is a genetic disorder involving uncontrolled,
widespread, extraskeletal bone growth, or heterotopic ossification (HO). In FOP patients, stem
cells called fibro/adipogenic progenitors (FAPs) follow an abnormal, osteogenic pathway. In the
present study, we investigate whether we can adapt these Acvr1 mutant FAPs, which are
exceptional at producing bone, to repair bone fractures in otherwise normal patients. The
primary aims of this study are (1) to devise and optimize a novel method to simulate bone
fractures less invasively in mice, and (2) to test whether mutant FAPs can form bone at fracture
sites in a controlled and localized manner. Through micro-CT, we visualize and quantify ectopic
bone volumes and observe that mutant FAPs form HO in both immunocompromised, SHOPrkdcscidHrhr (SCID) hosts and Acvr1tnR206H/+;R26NG/+;Tie2-Cre mice. However, HO does not appear
to be highly localized to bone fragments without the use of activin A monoclonal antibody.
Promisingly, donor bone fragments remain stable until at least 28 days post-transplantation.
Notably, one replicate exhibited a remarkable increase in bone volume and change in
morphology by day 14 followed by a decrease in bone volume by day 21 post-transplantation.
Future work should involve the use of activin A monoclonal antibody, a greater number of bone
fragments to maximize available bone morphogenetic proteins (BMPs), histological analyses to
visualize cell populations contributing to bone fragment changes (both stem cells and immune
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populations), and additional trials. Ultimately, this study is an innovative way to adapt an
aberrant process to treat another ailment.
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Introduction
The role of Acvr1 mutant fibro/adipogenic progenitors (FAPs) in fibrodysplasia ossificans
progressiva (FOP)
Fibrodysplasia ossificans progressiva (FOP) is a genetic disorder involving uncontrolled,
widespread, extraskeletal bone growth known as heterotopic ossification (HO) (Lees-Shepard et

Pasha 6
al., 2018a). Patients with FOP experience limited mobility and, in more severe cases, difficulty
opening their mouth if bone forms in the jaw (resulting in malnutrition) and trouble breathing if
bone forms in the thoracic cavity, leading to high morbidity (Kaplan et al., 2008).
FOP stems from a single amino acid change from arginine to histidine at position 206
(R206H) in the ACVR1 protein (Shore et al., 2006). The gene Acvr1 encodes bone
morphogenetic protein (BMP) type I receptor (Shore et al., 2006). Normally, BMP ligands (which
are present near bone) bind to BMP type I receptors and trigger a signaling cascade that leads
to osteogenesis, or bone formation (Lees-Shepard et al., 2018a). The Acvr1 mutation makes
bone growth go awry because it causes the BMP type I receptor to become hypersensitive to
BMPs (Culbert et al., 2014; Shen et al., 2009), resulting in robust and widespread bone growth
(Lees-Shepard et al., 2018b). Furthermore, the mutation in the Acvr1 gene alters the activity of
another protein known as activin A (Hatsell et al., 2015), which is ubiquitously expressed.
Normally, activin A binds to the ACVR1 receptor, triggers a signaling pathway known as
SMAD2/3 which inhibits BMP signaling, and leads to less bone growth (Hino et al., 2015).
However, in FOP, when activin A binds to the ACVR1 mutant complexes, it activates
osteogenesis instead of inhibiting it (Lees-Shepard et al., 2018b; Hatsell et al., 2015; Hino et al.,
2015). It is believed that the mutant receptor perceives activin A as a BMP ligand (Wolken et al.,
2018). Interestingly, activin A is an obligatory ligand for bone formation in FOP (Lees-Shepard et
al., 2018b; Hatsell et al., 2015).
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Fibro/adipogenic progenitor biology and their role in FOP pathogenesis
Our lab has recently identified a major contributing cell type to FOP called
fibro/adipogenic progenitors (FAPs), multipotent, mesenchymal stem cells that reside in the
muscle interstitium (Contreras et al., 2021). They are characterized by the expression of
platelet-derived growth factor receptor alpha (PDGFR𝛼), stem cell antigen-1 (Sca-1) (Joe et al.,
2010), and cluster of differentiation 34 (CD34) (Giordani et al. 2019); however, they are CD31
and CD45 negative (Molina et al., 2021). These criteria are used to isolate FAPs from other
muscle-resident cell types.
FAPs communicate cellularly and molecularly with various cell types present in muscle.
Importantly, they interact with satellite cells, or muscle stem cells (Mauro 1961; Molina et al.,
2021). Satellite cells assume a myogenic fate to regenerate injured skeletal muscle. If FAPs are
depleted, satellite cell numbers decrease after nine months (Wosczyna et al., 2019). FAPs help
facilitate myogenesis through the release of extracellular matrix (ECM) and immune-related
signaling factors (Scott et al., 2019; Molina et al., 2021). FAPs express chemokines and
cytokines that affect neutrophils, monocytes, and other immune cell types (Oprescu et al.,
2020). In fact, there is a positive correlation between inflammatory cell numbers and FAPs
proceeding injury (Molina et al., 2021).
Previous research investigates the role of FAPs in normal skeletal muscle repair and
regeneration. However, in many pathogenic contexts, they can differentiate into fibroblasts,
adipocytes, as well as osteogenic and chondrogenic cells depending on the presence or absence
of specific signaling factors in the environment (Joe et al., 2010; Uezumi et al., 2010; Contreras
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et al., 2021; Molina et al., 2021). For instance, transforming growth factor-𝛽 (TGF- 𝛽) triggers
fibrogenesis while dexamethasone, 3-isobutyl-1-methylxanthine, and insulin induce
adipogenesis (Uezumi et al., 2011; Molina et al., 2021). FAPs can undergo osteogenesis in the
presence of BMPs 2, 7, or 9 (Wosczyna et al., 2012; Lees-Shepard et al., 2018b). In fact,
Matrigel-BMP2 constructs containing FAPs form cartilage and bone in vivo (Wosczyna et al.,
2012). As previously discussed, activin A is necessary to stimulate Acvr1tnR206H mutant FAPs to
undergo endochondral ossification after skeletal muscle injury (Lees-Shepard et al., 2018b).
Normally, endogenous BMPs alone are not in sufficient quantity to stimulate osteogenesis in
FAPs. If activin A is blocked using an activin A antibody, then it cannot bind to the abnormal
type I BMP receptors and bone growth does not occur (Lees-Shepard et al., 2018b).
Given that FAPs with the Acvr1 mutation are exceptionally good at making bone and the
location of this process can be controlled using an agent that blocks activin A activity, like an
activin A antibody, a logical next step is to test whether we can take advantage of this ability
and use mutant FAPs to generate bone in a healthy person with a bone fracture. This feature
makes FAPs a particularly exciting future therapeutic. Their exceptional bone-producing
property while in the presence of BMPs (which are abundant near fracture sites) has the
potential to be “shut off” elsewhere by introducing an activin A antibody.

Cre-dependent knockin mouse model of FOP
Our lab has previously developed a mouse model of FOP in which Acvr1tnR206H
recombination is targeted to FAPs using Tie2-Cre (Lees-Shepard et al., 2018b). Cre recombinase
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is an enzyme that recombines DNA at specific sites. When manipulating genes, Cre cleaves at
loxP sites that flank a sequence of DNA, leading to gene insertion, deletion, inversion, or
translocation. Tissue or cell population specific Cre recombinases can be selected for spatial
and temporal control over the expression of a mutation, such as Tie2-Cre which specifically
targets FAPs as well as endothelial and hematopoietic stem cells (Kisanuki et al., 2001; Puri and
Bernstein, 2003; Takakura et al., 1998). Conditional knockins (Figure 1) are beneficial when
genetic mutations are lethal for the organism if expressed during embryogenesis or perinatally,
as seen in FOP (Kaplan et al., 2012). A tdTomato reporter stop cassette flanked by loxP sites in
intron 4 of Acvr1 not only prevents read-through transcription of the R206H mutation (located
downstream in exon 5) without Cre recombinase, but also labels unrecombined cells red (LeesShepard et al., 2018b); the CAG promoter/enhancer drives this stop cassette (Lees-Shepard et
al., 2018b). Our FOP mouse model enables us to determine recombination efficiency through
fluorescent reporters (Lees-Shepard et al., 2018b). R26NG indicates Cre expression and
fluoresces green from green fluorescent protein (GFP) (Lees-Shepard et al., 2018b). Without
Cre, the stretch of DNA containing the tdTomato reporter stop cassette does not get excised,
the Acvr1 mutation characteristic to FOP does not get transcribed, and the unrecombined cells
appear red (Lees-Shepard et al., 2018b).
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Figure 1: Schematic of our Cre-dependent knockin mouse model involving recombination of the Acvr1tnR206H
allele. Created with BioRender.com

Bone fractures: preexisting treatments and prevalence
Bone fractures and the surgical approaches that fix them have been an area of great
investigation within regenerative medicine and orthopedics. Bone fractures are some of the
most common orthopedic-related injuries, resulting from automobile accidents, falls, sportsrelated injuries, etc. While healing occurs during the 6-8 weeks post injury, complications—
from excessive movement at the site of fracture to substance abuse—can prolong repair (Perez
et al., 2018).
Currently, the treatment of choice for nonunion fractures, which are severe fractures
that do not heal without surgical intervention, is a bone graft—specifically autografts (coming

Pasha 11
from the patient), allografts (coming from a donor), and synthetic grafts (derived from stem
cells) (Perez et al., 2018). However, each technique has numerous drawbacks in terms of their
effectiveness, chance of further complications, and costs. Allografts can cause an infection or
be rejected by the patient’s immune system. They also require extensive sterilization which can
diminish osteoconduction and osteoinduction (Cipriano et al., 2019). Autografts, while solving
the issue of immune rejection, have several drawbacks including morbidity at the donor site,
muscle weakness, and surgical complications (Perez et al., 2018). They are also more invasive
due to the need for a second surgery to harvest the grafting tissue (Cipriano et al., 2019).
Synthetic grafts often cannot withstand long term wear and tear. In fact, as high as 60% of
grafts fail (Perez et al., 2018). Grafts are quite costly; approximately 1.6 million are
administered in the U.S. every year, amounting to over $244 billion (Perez et al., 2018).
Notably, traditional stem cell therapies involving bone marrow mesenchymal stem cells
can be ineffective because they often lose their osteogenic ability when handled in the lab
(unpublished data). Empirical evidence suggests that Acvr1 mutant FAPs maintain their
osteogenic capacity longer and perform better both in culture and in vivo. Investigating the
potential therapeutic ability of these FAPs in treating bone fractures in otherwise normal
patients is a fascinating clinical application.

Hypotheses and experimental aims
Our study seeks to determine whether mutant FAPs can be introduced in a localized
fashion at the site of bone fracture in mice and repair bone in an efficient and controlled
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manner. In addition, we want to know whether administering an antibody for activin A
alongside mutant FAPs helps “shut off” mutant FAP activity farther away from the immediate
fracture site. We hypothesize that, if Acvr1 mutant FAPs are injected at the site of a bone
fracture in mice, then mutant FAPs will assume an osteogenic fate and repair the fracture faster
than mice injected with normal FAPs or traditionally used mesenchymal stem cells. Additionally,
we hypothesize that, after mutant FAP introduction along with the activin A antibody, bone
growth will only occur in the immediate vicinity of the fracture, where BMP ligands stimulate
them to participate in bone repair. Our study also seeks to create and optimize a novel method
to simulate bone fractures in mice without physically fracturing bones since such protocols are
not well established in the mouse model. Instead of physically fracturing bones (which is
invasive and requires particular analgesics), we hypothesize that transplanting bone fragments
from a donor mouse into the gastrocnemius muscle of a host mouse can model a bone fracture
at the cut ends of donor fragments.

Materials and Methods
Animals
SHO-PrkdcscidHrhr and Acvr1tnR206H/+;R26NG/+;Tie2-Cre mice were housed and cared for in
accordance with the University of Connecticut IACUC policies and procedures to ensure animal
welfare. Mice were genotyped by checking for reporter fluorescence and conducting
polymerase chain reaction (PCR).
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Fluorescence-activated cell sorting (FACS) and cell injection
ACVR1(R206H)-expressing FAPs were obtained as previously described (Biswas and
Goldhamer, 2016). Briefly, muscle dissociation buffer contains Dulbecco’s Modified Eagle
Medium (DMEM) (Life Technologies), 2 mg/mL Collagenase Type II (Worthington Biochemical)
and 0.3 mg/mL Dispase (Invitrogen). Hindlimb muscle tissue was harvested and placed in
enough dissociation buffer (Figure 2A) to facilitate mincing, which involved cutting the muscle
tissue with scissors for 10 minutes and forming a paste-like consistency (Figure 2B). Samples
resided in muscle dissociation buffer for approximately 1.5 hours with gentle trituration using a
pipette and/or shaking every 15 minutes. Cold media containing 20% Fetal Bovine Serum (FBS)
(R&D Systems) in DMEM was used to quench digestion. The solution was filtered using 100 μm
and 70 μm strainers (Corning; Fisher Scientific) (Figure 2C) and underwent centrifugation. After
further washing and resuspension as described (Biswas and Goldhamer, 2016), samples were
incubated with the appropriate antibodies to isolate Acvr1 mutant FAPs from other cell types
present in hindlimb muscle. FAPs were separated based on the presence of PDGFRα and SCA-1
and the absence of myeloid and endothelial markers (CD45 and CD31, respectively) using the
FACS Aria II (BD Biosciences) (Figure 2D). Mutant FAPs were separated from wild type by
selecting cells not expressing tdTomato, demonstrating recombination. Approximately 450,000
FAPs were collected and cultured for transplantation. Ultimately, one dose of FAPs suspended
in Dulbecco’s Phosphate Buffered Saline (DPBS) (Life Technologies) was administered at 1 x 106
cells per 50 μL injection using an insulin syringe (Exel International) (Lees-Shepard et al., 2018b).
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Bone fragment transplantation
A bone fracture was simulated by embedding either one-4mm fragment or two-2mm
fibular bone fragments into the gastrocnemius muscle of FOP mice (Figure 3). The former was
conducted in SHO-PrkdcscidHrhr mice before methods were optimized to increase the amount of
exposed, cut bone by increasing the number of fragments to two. Bone fragments were
collected from wild-type mice, serving as a scaffold and source of BMPs. A pilot hole was
introduced using a 25-gauge needle (Fisher Scientific) intramuscularly to aid in fragment
insertion. Bone fragments were inserted intramuscularly parallel to the grain of the
gastrocnemius muscle, and bone volumes were quantified at 0, 7, 14, 21, and 28 days posttransplantation.
During pilot experiments in SHO-PrkdcscidHrhr hosts, one bone fragment was inserted.
The left hindlimb contained a bone fragment and mutant FAPs, while the right hindlimb
contained only a bone fragment and served as a control to test whether wild-type resident FAPs
would contribute at all to HO. Immunocompromised mice eliminate the issue of immune
rejection when transplanting foreign cells (Lees-Shepard et al., 2018b). To introduce more
nucleation sites for potential HO, two fragments were transplanted when using
Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts.

Cardiotoxin-mediated injury to trigger HO in Acvr1tnR206H/+;R26NG/+;Tie2-Cre mouse
model
Cardiotoxin injury was conducted after administering isoflurane anesthesia to the mice.
To trigger injury-induced HO in our FOP mouse model, 100 μL injections of 10 μM cardiotoxin
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(Sigma) were conducted bilaterally into the mid belly of the gastrocnemius muscle the day prior
to bone fragment transplantation (Figure 5).

Micro-CT
Under isoflurane anesthesia, mice were imaged at 0, 7, 14, 21, and 28 days post bone
fragment transplantation (Figures 2 and 3)—ideal timepoints from our previous studies (LeesShepard et al., 2018b)—using the IVIS SpectrumCT model 128201 (Perkin-Elmer) to see the
mouse’s bones in real time, confirm fragment presence, track bone fragment stability, and
quantify FAP-mediated bone deposition. Assessing bone fragment stability was crucial to
ensure processes like endogenous bone resorption or an innate immune response did not
degrade the fragments. The setting employed on the IVIS SpectrumCT was medium resolution
acquisition mode, which scans hindlimbs. 3D Slicer (http://www.slicer.org), a software that uses
3-D reconstruction to generate models for visualization and volumetric quantification, was
utilized to determine bone volumes and pseudo color fragments and HO to generate images.
This quantification of bone growth at each time point served as a metric to compare
experimental (left) and control (right) limbs within the same mouse as well as across different
replicates.
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Results
Bone fragment transplantation and Acvr1 mutant FAP injection into SHO-PrkdcscidHrhr
hosts form HO that is not highly localized to bone fragments
Hindlimb muscle tissue was harvested from FOP (Acvr1tnR206H/+;R26NG/+;Tie2-Cre) mice
and dissociated to obtain a single cell suspension as previously described (Figure 2). Adherent
cells were grown in culture prior to fluorescence-activated cell sorting (FACS) to isolate mutant
FAPs (fluorescing green under a microscope for easy visualization) (Figure 2D).

Figure 2: Muscle collection and fluorescence-activated cell sorting (FACS) gating strategy. (A) Harvested hindlimb
muscle tissue in a 35 mm x 10 mm Petri dish containing enough muscle dissociation buffer to partially submerge
the tissue. (B) Hindlimb muscle tissue proceeding approximately 10 minutes of mincing with scissors, resulting in a
paste-like consistency. (C) Strainers (100 μm and 70 μm) used to filter solutions of dissociation media, cold media,
and minced hindlimb muscle tissue. (D) FACS gating strategy for collection of TdTomato-/CD31-/CD45/PDGFRα+/SCA-1+ FAPS. This mutant FAP subpopulation was grown in culture until enough cells were generated
prior to intramuscular injection. FACS was conducted by graduate student mentor Lorraine Apuzzo.
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Figure 3: Schematic of bone fragment transplantation study workflow using SHO-PrkdcscidHrhr hosts.

At day 14 post-transplantation of bone fragment and Acvr1 mutant FAPs (Figure 3),
ectopic bone growth was observed in the left hindlimb (LHL) in the absence of activin A
monoclonal antibody (Figure 4A). However, it was not highly localized to the fragment (Figure
4A). LHL HO was 11.52 mm3, 2.31 mm3, and 7.79 mm3 for trials 1, 2, and 3 respectively,
demonstrating variability among replicates (Figure 4B). At day 14 post-transplantation, trial 1
had the highest HO volume but lowest fragment volume (0.83 mm3); trial 2 had the lowest HO
volume but highest fragment volume (2.31 mm3); trial 3 had intermediate HO and fragment
volumes (1.27 mm3) (Figure 4B). In the right hindlimb (RHL) control, a bone fragment alone was
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transplanted to track its stability without mutant FAPs present. RHL fragment volumes were
relatively consistent at 1.59 mm3, 1.24 mm3, and 1.32 mm3 for trials 1, 2, and 3, respectively
(Figure 4B). Furthermore, endogenous wild-type FAP contribution was not observed due to the
lack of HO in the right hindlimb at day 14 in all three trials (Figure 4B). Additional trials must be
conducted to determine if the lack of HO localization to the bone fragments was a technical
error or if the methodology needs to be amended. One potential source of high variability in HO
in the LHL was technical error, namely cells settling in solution prior to transplantation.

Figure 4: Micro-CT quantification of bone growth (heterotopic ossification, HO) proceeding bone fragment and
mutant FAP transplantation into an immunocompromised mouse. (A) At day 14 post-transplantation, mutant
FAPs formed bone (blue) in the absence of activin A monoclonal antibody but did not co-localize with the
transplanted bone fragments (red). (B) HO and bone fragment volumes (mm3) were quantified for experimental
(left hindlimb, LHL) and control (right hindlimb, RHL) samples. Statistics and additional trials pending. Micro-CT
scans were processed and bone volumes were quantified by graduate student mentor Lorraine Apuzzo using 3D
Slicer.
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Bone fragment transplantation into Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts forms HO that is
not highly localized to bone fragments
A different approach that we investigate here is to transplant bone fragments into host
mice with endogenous mutant FAPs, namely mice with the FOP mutation, to circumvent
localized cell transplantation (Figure 5). Bilateral cardiotoxin injections were conducted in the
gastrocnemius muscles of Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts while bone fragments harvested
from wild-type donors were transplanted into the left hindlimb only (Figure 5; Figure 6A, C, E,
G). Since the host was not immunocompromised, immune rejection was a potential concern.

Figure 5: Schematic of bone fragment transplantation study workflow using Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts

In replicate 1, on day 14 post-transplantation, both fragments underwent morphological
changes, as evidenced by the mushroom-like structure at the end of the pseudo-colored red
fragment (Figure 6E). Between day 7 and 14, there was a dramatic increase in red bone
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fragment size from 0.412594 mm3 to 0.97875 mm3 (Figure 9A-C). The blue fragment stayed
relatively constant in bone volume between day 7 and 14, with volumes of 0.634922 mm3 and
0.62859 mm3, respectively (Figure 9A-C). Interestingly, both red and blue fragments decreased
in volume between days 14 and 21 (Figure 9A-C). The blue fragment went from 0.62859 mm3 to
0.424828 mm3 while the red fragment went from 0.97875 mm3 to 0.261141 mm3 (Figure 9A-C).
RHL HO also decreased from 26.9253 mm3 to 16.6075 mm3 in contrast to LHL HO, which
increased from 27.3337 mm3 to 31.201 mm3 between day 14 and 21 (Figure 6B, D, F, H; Figure
9A-C). Scanning halted at day 21 due to the premature death of the host mouse.

Figure 6: Replicate 1 micro-CT quantification of HO proceeding bone fragment transplantation into FOP host.
Micro-CT conducted at days 0, 7, 14, and 21 post-transplantation revealed changes in bone volume and
morphology of transplanted fragments as well as the presence of cardiotoxin-induced HO. Bone volume (mm3) was
quantified for experimental (LHL) and control (RHL) samples. Within each time point shown above, the left
hindlimb is the left panel and the right hindlimb is the right panel. Note: images were cropped and resized to
preserve consistent sizing of anatomical landmarks.
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Replicate 2 also demonstrated fragment stability as well as changes in size and
morphology (Figure 7A, C, E, G, I). LHL HO consistently increased between every time point
while the blue fragment increased from day 0 to day 7 (0.391078 mm3 to 0.462797 mm3) but
decreased steadily at all remaining time points; the red fragment also increased from day 0 to 7
(0.385594 mm3 to 0.415547 mm3) but steadily decreased from day 7 to day 28 (Figure 9A-C).
RHL HO peaked at day 14 (2.54728 mm3), decreased at day 21 (1.41539 mm3), and increased
again at day 28 (1.85161 mm3) (Figure 7 B, D, F, H, J; Figure 9A-C).

Figure 7: Replicate 2 micro-CT quantification of HO proceeding bone fragment transplantation into FOP host.
Micro-CT conducted at days 0, 7, 14, 21, and 28 post-transplantation revealed changes in bone volume and
morphology of transplanted fragments as well as the presence of cardiotoxin-induced HO. Bone volume (mm3) was
quantified for experimental (LHL) and control (RHL) samples. Within each time point shown above, the left
hindlimb is the left panel and the right hindlimb is the right panel. Note: images were cropped and resized to
preserve consistent sizing of anatomical landmarks.

In replicate 3, LHL HO increased from day 7 to 14 (0.0434531 mm3 to 1.55714 mm3),
decreased to 0.550547 mm3 at day 21, and increased again to 0.77625 mm3 by day 28 (Figure
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8A, C, E, G, I; Figure 9A-C). The blue fragment steadily decreased from day 0 (0.694828
mm3) onwards until plateauing around day 21 at 0.450562 mm3 (Figure 9A-C). The red
fragment was 0.65475 mm3, 0.647578 mm3, 0.65391 mm3, 0.521016 mm3, and 0.421031 mm3
at day 0, 7, 14, 21, and 28, respectively—remaining steady in volume until day 14 and
decreasing at subsequent time points (Figure 9A-C). RHL HO peaked at day 21 (6.09441 mm3)
and decreased to 2.14903 mm3 by day 28 (Figure 8B, D, F, H, J; Figure 9A-C).

Figure 8: Replicate 3 micro-CT quantification of HO proceeding bone fragment transplantation into FOP host.
Micro-CT conducted at days 0, 7, 14, 21, and 28 post-transplantation revealed changes in bone volume and
morphology of transplanted fragments as well as the presence of cardiotoxin-induced HO. Bone volume (mm3) was
quantified for experimental (LHL) and control (RHL) samples. Within each time point shown above, the left
hindlimb is the left panel and the right hindlimb is the right panel. Note: images were cropped and resized to
preserve consistent sizing of anatomical landmarks.
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Figure 9: Tabular and graphical representations of bone volume quantification in all three replicates. Statistics
and additional trials pending.

Discussion and Future Directions
The use of Acvr1tnR206H mutant FAPs in bone fracture therapeutics has not previously
been explored despite their ability to form robust HO in FOP models as well as empirical
evidence suggesting their better osteogenic capacity and superior performance both in culture
and in vivo. With nonunion fractures requiring effective and efficient bone grafts in surgical
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interventions, mutant FAPs may be a viable alternative to traditional bone marrow
mesenchymal stem cell therapies if properly regulated and localized to fracture sites.
While optimizing our novel bone fragment transplantation technique to model bone
fractures less invasively, an early replicate (data not shown) peculiarly showed the
disappearance of the bone fragment on day 7 micro-CT scans despite being present on day 0
scans. We speculated that this was due to the fragment falling out of the intramuscular pilot
hole as no other replicate demonstrated this result. In subsequent experiments, careful
attention was paid to ensure fragments were sufficiently embedded within the muscle and
adequate skin glue was applied to close the incision site.
In our first experiment testing whether mutant FAPs colocalize with fragments in
immunocompromised hosts, there was ectopic bone growth in the experimental LHL in the
absence of activin A monoclonal antibody that was not highly localized to the fragment. SCID
mice were empirically less resilient during surgery, some dying during the procedure which we
speculate was due to prolonged isoflurane exposure. As such, mutant FAP cell injection was
conducted the day after bone fragment transplantation. While this enabled the host mouse to
rest and avoid prolonged anesthesia, it may have been advantageous to inject the cells into the
same pilot hole containing the bone fragments as it is unclear whether HO not localizing to
bone fragments was caused by insufficient BMPs or injecting mutant FAPs distant from our
fracture site model. Among replicates, there was also high variability in HO formation. Cells
settling in solution prior to injection was a potential source of high variability in HO in the LHL.
This concern can be mitigated by using a pipette to resuspend the cells in the Eppendorf tube
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directly before injection. Additionally, some solution seeped out of the hole of entry during cell
injection; although the solution was extracted by the insulin syringe and reinjected, this could
have caused a slightly lower concentration of mutant FAP cells being injected and potentially
lower HO volumes.
To circumvent cell transplantation altogether, Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts were
used instead so that mutant FAPs were available endogenously and only bone fragments were
transplanted. Intramuscular bone fragment transplantation was not sufficient injury to induce
HO as evidenced by a lack of ectopic bone in micro-CT scans weeks after transplantation (data
not shown). As such, cardiotoxin was injected into both gastrocnemius muscles to stimulate
mutant FAP-mediated osteogenesis proceeding sufficient muscle injury. With this method,
immune rejection was a potential concern; nonetheless, micro-CT scans conducted every 7 days
from day 0 to 28 post-transplantation revealed bone fragment stability. Bone volumetric data
showed that replicate 1 underwent the most dramatic change in morphology with the
formation of a mushroom-like cap at the end of the red fragment appearing between day 7 and
14 and disappearing between day 14 and 21. As noted, RHL HO in replicate 1 decreased from
26.9253 mm3 to 16.6075 mm3 while LHL HO increased from 27.3337 mm3 to 31.201 mm3
between day 14 and 21. We speculate that this inverse correlation may be due to an immune
reaction and inflammatory response to donor fragments that contributed to the increase in HO
volume between days 14 and 21. However, histological staining between these time points is
pending and will provide further insights into the cell types contributing to this phenotype.
While replicates 2 and 3 did not undergo as dramatic of an increase in bone fragment volume,
both demonstrated fragment stability as well as changes in size and morphology. In replicate 2,
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both red and blue fragments increased in volume from day 0 to day 7 but decreased steadily at
all remaining time points as previously mentioned. In replicate 3, the blue fragment steadily
decreased from day 0 onwards until plateauing around day 21, while the red fragment
remained steady in volume until day 14 and decreased at subsequent time points. It is unclear
whether this decrease in volume was due to endogenous bone resorption processes or an
immune response to foreign cells without conducting histological analyses.
The lack of colocalization between transplanted bone fragments and mutant FAPmediated HO could be due to an insufficient quantity of BMPs. While the number of fragments
was altered from 1 to 2, future iterations should use a greater number of bone fragments. This
was not initially conducted because of the need to introduce additional pilot holes using a thingauged needle at the time of transplantation. Crushing donor bone into small pieces,
suspending it in solution, and injecting it intramuscularly may be another way to maximize cut
bone and available BMPs. The rationale for not injecting BMPs directly despite it being the most
straightforward approach was that it deviates substantially from a bone fracture model; bone
fragments provide a biologically active scaffold. However, perhaps fragments can be
supplemented with BMP injection, as many orthopedic surgeons have been doing since the
discovery of BMPs by Urist et al. (Grgurevic et al., 2017; Johnson et al., 1988).
Furthermore, our results corroborate male-female sex differences in HO volume
observed by other researchers in the lab, with females generating higher bone volumes
compared to males (Apuzzo et al., unpublished observations). Replicates 1 and 2 were females
while replicate 3 was male, and the male host generated less HO than its female counterparts.
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If repeated, greater numbers of each sex should be included in our study. It is crucial to track
the sex of both donor and host mice due to the sex-dependent disparity in HO seen in our
mouse model of FOP.
Taken together, these data demonstrate that Acvr1 mutant FAP-mediated, cardiotoxininduced HO can successfully occur in our novel bone fragment transplantation assay. While HO
was not localized to simulated fracture sites in both SHO-PrkdcscidHrhr hosts and
Acvr1tnR206H/+;R26NG/+;Tie2-Cre hosts, these experiments are important foundations in
optimizing our intramuscular bone fragment transplantation protocol.
In addition to taking bone scans using the micro-CT, the limbs from these specimens
should be collected at various time points, fixed, sectioned, and stained to observe the tissue
environment at the microscopic level. Histology will reveal the spatial composition of the region
between muscle and bone, where mutant FAPs (fluorescing green) localize in relation to the
bone fragments, and, perhaps, miniscule bone growths undetected by micro-CT. These
strategies can help determine whether mutant FAPs engrafted properly and survived as well as
their exact position in the limb. Bone fragments should be collected from mice with fluorescent
reporters to track lineage contribution to bone formation. In subsequent replicates, tissue
should be collected for histological preparation between day 14 and 21 (when the mushroom
cap morphology appeared in replicate 1) to visualize at the cellular level which cells are
contributing to bone growth at the ends of fragments. Additionally, using inflammatory and
immune cell-identifying markers can provide additional insights into the host’s immune
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response in the gastrocnemius muscle of the experimental limb proceeding bone fragment
transplantation.
Before we can draw definitive conclusions about HO localization, future iterations
should also incorporate the activin A monoclonal antibody (Acceleron Pharma), administered in
a single, intraperitoneal injection on the day of transplantation at a dose of 10 mg/kg (LeesShepard et al., 2018b). Additionally, while a primary aim of the present study was to design and
optimize a less invasive way to model bone fractures without physically fracturing bones, an
important step in between their successful adaptation to the clinic is injecting mutant FAPs
directly at the site of a fracture.
Ultimately, when fractures fail to heal on their own and require surgery to repair, it is
imperative that physicians provide efficient and long-term solutions to prevent further bone
complications. While traditional stem cells often lose their osteogenic ability when handled in
the lab, the mutant FAP cell model that my project seeks to test could solve such issues. Above
all, ensuring that bone cell formation is strictly localized to the fracture site will be crucial to
bringing this idea from the bench top to the operating room.
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